NCT01567813View on ClinicalTrials.gov

Post-Licensure Study of the Safety of GARDASIL™ in Males (V501-070)

CompletedOBSERVATIONAL

Enrollment

114,035

Participants

Timeline

Start Date

June 23, 2011

Primary Completion Date

June 1, 2019

Study Completion Date

June 1, 2019

Conditions

Human Papilloma Virus Infection

All Listed Sponsors

lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT01567813 - Post-Licensure Study of the Safety of GARDASIL™ in Males (V501-070) | Biotech Hunter | Biotech Hunter